Clinical Trial for Patients with Small-Cell Lung Cancer
Patients with newly diagnosed small-cell lung cancer (SCLC) may wish to consider participating in a clinical trial. Some clinical trials, such as the NORTH trial discussed below, enable patients to receive standard treatment for their disease plus the opportunity to also receive an experimental agent.
The NORTH clinical trial is designed to assess the impact on patient outcomes of adding the experimental agent, IMGN901, to standard treatment for newly diagnosed SCLC. All patients enrolled in the trial will receive standard treatment, a combination of the drugs etoposide and carboplatin. Two of every three patients enrolled will also receive IMGN901.
This site includes information to help you learn more about this trial.